JP7633989B2 - Hpk1阻害剤およびその使用 - Google Patents
Hpk1阻害剤およびその使用 Download PDFInfo
- Publication number
- JP7633989B2 JP7633989B2 JP2022500151A JP2022500151A JP7633989B2 JP 7633989 B2 JP7633989 B2 JP 7633989B2 JP 2022500151 A JP2022500151 A JP 2022500151A JP 2022500151 A JP2022500151 A JP 2022500151A JP 7633989 B2 JP7633989 B2 JP 7633989B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- chr
- halogen
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/094634 | 2019-07-04 | ||
| CN2019094634 | 2019-07-04 | ||
| PCT/CN2020/100134 WO2021000935A1 (en) | 2019-07-04 | 2020-07-03 | Hpk1 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538923A JP2022538923A (ja) | 2022-09-06 |
| JP2022538923A5 JP2022538923A5 (cg-RX-API-DMAC7.html) | 2023-07-11 |
| JP7633989B2 true JP7633989B2 (ja) | 2025-02-20 |
Family
ID=74100919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500151A Active JP7633989B2 (ja) | 2019-07-04 | 2020-07-03 | Hpk1阻害剤およびその使用 |
| JP2023500011A Active JP7759374B2 (ja) | 2019-07-04 | 2021-07-02 | Hpk1阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500011A Active JP7759374B2 (ja) | 2019-07-04 | 2021-07-02 | Hpk1阻害剤およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12612424B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3994133A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7633989B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220044495A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114555585B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020298649B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022000064A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3145973A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4175951T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2981368T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4175951T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289612B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA56462A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022000271A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI878319B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021000935A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533938A (ja) * | 2019-07-04 | 2023-08-07 | キル・レガー・セラピューティクス・インコーポレーテッド | Hpk1阻害剤およびその使用 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| EP4090663A1 (en) | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| CN116456985A (zh) * | 2020-09-23 | 2023-07-18 | 深圳市原力生命科学有限公司 | 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法 |
| US20230399327A1 (en) * | 2020-10-28 | 2023-12-14 | Adlai Nortye Biopharma Co., Ltd. | High activity hpk1 kinase inhibitor |
| WO2022174253A1 (en) | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN117295737A (zh) * | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| CN117295748A (zh) * | 2021-03-08 | 2023-12-26 | 缆图药品公司 | Map4k1抑制剂 |
| JP2024510176A (ja) * | 2021-03-08 | 2024-03-06 | ブループリント メディシンズ コーポレイション | Map4k1阻害剤 |
| TW202246263A (zh) * | 2021-03-23 | 2022-12-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Hpk1激酶抑制劑化合物 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN117377673A (zh) * | 2021-03-29 | 2024-01-09 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| TW202304906A (zh) * | 2021-04-08 | 2023-02-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 高活性hpk1激酶抑制劑 |
| MX2024000751A (es) * | 2021-07-14 | 2024-03-25 | Blueprint Medicines Corp | Compuestos heterociclicos como inhibidores de map4k1. |
| WO2023001794A1 (en) | 2021-07-20 | 2023-01-26 | Astrazeneca Ab | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
| EP4377318A4 (en) * | 2021-07-30 | 2025-06-04 | BeiGene, Ltd. | PYRROLO[2,3-B PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND USE THEREOF |
| WO2023083299A1 (zh) * | 2021-11-12 | 2023-05-19 | 微境生物医药科技(上海)有限公司 | 作为hpk1抑制剂的稠环化合物 |
| WO2023134608A1 (zh) * | 2022-01-11 | 2023-07-20 | 微境生物医药科技(上海)有限公司 | 作为hpk1抑制剂的稠环化合物 |
| WO2023245329A1 (en) * | 2022-06-20 | 2023-12-28 | Biofront Ltd | Multi-kinase inhibitors, compositions thereof, and methods of using the same |
| CN117447470B (zh) * | 2023-02-20 | 2026-05-01 | 杭州医学院 | 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用 |
| CN116813692A (zh) * | 2023-06-29 | 2023-09-29 | 凌科药业(杭州)有限公司 | 含磷化合物、其药物组合物及其用途 |
| WO2025096647A1 (en) * | 2023-10-30 | 2025-05-08 | Nimbus Saturn, Inc. | Methods of treating tumors |
| WO2025137168A2 (en) | 2023-12-19 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Salt and solid forms of a hpk1 inhibitor |
| WO2025255343A1 (en) * | 2024-06-06 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Pyrrolopyrimidine inhibitors of wild-type and mutant lrrk2 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009084695A1 (ja) | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | 2-アミノキナゾリン誘導体 |
| JP2009542604A (ja) | 2006-07-06 | 2009-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 4−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用 |
| JP2010514693A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Pdk1阻害のためのキナゾリン |
| CN104876914A (zh) | 2014-02-28 | 2015-09-02 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| WO2015143692A1 (en) | 2014-03-28 | 2015-10-01 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
| CN106188029A (zh) | 2015-05-05 | 2016-12-07 | 山东轩竹医药科技有限公司 | 二并环类间变性淋巴瘤激酶抑制剂 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2007041511A2 (en) | 2005-09-30 | 2007-04-12 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| WO2007135398A1 (en) | 2006-05-22 | 2007-11-29 | Astrazeneca Ab | Indole derivatives |
| WO2008110508A1 (en) | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
| US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| EP2248907A1 (en) | 2009-05-08 | 2010-11-10 | Rijksuniversiteit Groningen | Gluco-oligosaccharides comprising (alpha 1-->4) and (alpha 1-->6) glycosidic bonds, use thereof, and methods for providing them |
| WO2012135631A1 (en) * | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| US9708336B2 (en) | 2014-01-22 | 2017-07-18 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| ES2921257T3 (es) | 2016-06-20 | 2022-08-22 | Daegu Gyeongbuk Medical Innovation Found | Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US11180482B2 (en) | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| EP3587422A4 (en) | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| EP3596075B1 (en) | 2017-03-15 | 2023-10-11 | F. Hoffmann-La Roche AG | Azaindoles as inhibitors of hpk1 |
| US20200071326A1 (en) | 2017-04-14 | 2020-03-05 | Syros Pharmaceuticals, Inc. | Tam kinase inhibitors |
| WO2018215668A1 (en) | 2017-05-26 | 2018-11-29 | Glenmark Pharmaceuticals S.A. | Novel inhibitors of map4k1 |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CN109721620B (zh) | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
| WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020235902A1 (ko) | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
| WO2021000935A1 (en) | 2019-07-04 | 2021-01-07 | Qilu Regor Therapeutics Inc. | Hpk1 inhibitors and uses thereof |
-
2020
- 2020-07-03 WO PCT/CN2020/100134 patent/WO2021000935A1/en not_active Ceased
- 2020-07-03 BR BR112022000064A patent/BR112022000064A2/pt not_active Application Discontinuation
- 2020-07-03 JP JP2022500151A patent/JP7633989B2/ja active Active
- 2020-07-03 CA CA3145973A patent/CA3145973A1/en active Pending
- 2020-07-03 AU AU2020298649A patent/AU2020298649B2/en active Active
- 2020-07-03 MX MX2022000271A patent/MX2022000271A/es unknown
- 2020-07-03 MA MA056462A patent/MA56462A/fr unknown
- 2020-07-03 EP EP20834163.6A patent/EP3994133A4/en active Pending
- 2020-07-03 KR KR1020227003145A patent/KR20220044495A/ko active Pending
- 2020-07-03 IL IL289612A patent/IL289612B2/en unknown
- 2020-07-03 US US17/624,514 patent/US12612424B2/en active Active
- 2020-07-03 TW TW109122604A patent/TWI878319B/zh active
- 2020-07-03 CN CN202080057904.1A patent/CN114555585B/zh active Active
-
2021
- 2021-07-02 JP JP2023500011A patent/JP7759374B2/ja active Active
- 2021-07-02 KR KR1020237003551A patent/KR20230035061A/ko active Pending
- 2021-07-02 EP EP21742686.5A patent/EP4175951B1/en active Active
- 2021-07-02 DK DK21742686.5T patent/DK4175951T3/da active
- 2021-07-02 US US18/013,402 patent/US12617811B2/en active Active
- 2021-07-02 FI FIEP21742686.5T patent/FI4175951T3/fi active
- 2021-07-02 CN CN202180053862.9A patent/CN116096370B/zh active Active
- 2021-07-02 WO PCT/CN2021/104206 patent/WO2022002237A1/en not_active Ceased
- 2021-07-02 ES ES21742686T patent/ES2981368T3/es active Active
- 2021-07-02 MX MX2023000025A patent/MX2023000025A/es unknown
- 2021-07-02 AU AU2021299849A patent/AU2021299849A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009542604A (ja) | 2006-07-06 | 2009-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 4−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用 |
| JP2010514693A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Pdk1阻害のためのキナゾリン |
| WO2009084695A1 (ja) | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | 2-アミノキナゾリン誘導体 |
| CN104876914A (zh) | 2014-02-28 | 2015-09-02 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| WO2015143692A1 (en) | 2014-03-28 | 2015-10-01 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
| CN106188029A (zh) | 2015-05-05 | 2016-12-07 | 山东轩竹医药科技有限公司 | 二并环类间变性淋巴瘤激酶抑制剂 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533938A (ja) * | 2019-07-04 | 2023-08-07 | キル・レガー・セラピューティクス・インコーポレーテッド | Hpk1阻害剤およびその使用 |
| JP7759374B2 (ja) | 2019-07-04 | 2025-10-23 | レゴー・ファーマシューティカルズ,インコーポレーテッド | Hpk1阻害剤およびその使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12612424B2 (en) | HPK1 inhibitors and uses thereof | |
| CN109348715B (zh) | 作为tam抑制剂的吡咯并三嗪化合物 | |
| JP7086395B2 (ja) | 置換インドールMcl-1阻害剤 | |
| DK2376478T3 (en) | Pyridyloxyindoline inhibitors for VEGF-R2 and its use in the treatment of diseases | |
| CN115605466B (zh) | 用于治疗癌症的经取代的氧代异吲哚啉化合物 | |
| AU2012284540B2 (en) | TRPV4 antagonists | |
| KR20170066566A (ko) | Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도 | |
| CN108602776A (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
| WO2015017610A1 (en) | Syk inhibitors | |
| IL325136A (en) | Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a | |
| RU2839132C2 (ru) | Ингибиторы hpk1 и их применение | |
| HK40090215A (en) | Hpk1 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230703 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20231130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240216 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241030 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250207 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7633989 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
| R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |